SNTA Key Stats
- SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E Dec 2
- 2 Speculative Biopharmas Way Under Analyst Price Targets Nov 22
- Synta Announces Publications Demonstrating Ganetespib Activity in Triple-Negative Breast Cancer Models noodls Nov 21
- 5 Stocks Insiders Love Right Now Nov 20
- Synta Pharmaceuticals (SNTA) Catches Eye: Stock Surges 15.2% - Tale of the Tape Zacks Nov 19
- Synta Pharmaceuticals (SNTA) Catches Eye: Stock Surges 15.2% Nov 19
- Why Voxeljet, Synta Pharmaceuticals, and The Container Store Are Today's 3 Best Stocks Nov 18
- SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 18
- Insiders Buy Shares at Synta Pharmaceuticals and Aircastle Minyanville Nov 18
- Synta Pharmaceuticals Closes Public Offering of Common Stock noodls Nov 18
SNTA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Synta Pharmaceuticals is down 34.56% over the last year vs S&P 500 Total Return up 30.90%, Dendreon down 36.36%, and Ariad Pharmaceuticals down 81.42%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for SNTA
Pro Strategies Featuring SNTA
Did Synta Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Synta Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing & commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions like cancer and chronic inflammatory diseases.